Cadian Capital Management, LP Incyte Corp Transaction History

Cadian Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$63.56 - $88.17 $7.5 Million - $10.4 Million	-118,016 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$58.5 - $69.94 $3.33 Million - $3.99 Million	-56,984 Reduced 32.56%	118,016 $7.51 Million
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $10.8 Million - $13 Million	175,000 New	175,000 $12.1 Million
Q2 2018 Aug 13, 2018	SELL	$60.85 - $83.98 $912,750 - $1.26 Million	-15,000 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$83.06 - $100.98 $1.25 Million - $1.51 Million	15,000 New	15,000 $1.25 Million
Q4 2017 Feb 13, 2018	SELL	$93.56 - $116.6 $8.24 Million - $10.3 Million	-88,100 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $9.62 Million - $12.2 Million	88,100	88,100 $10.3 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Cadian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cadian Capital Management, LP with notifications on news.